Search Results for Pharma

Royalty Pharma to Showcase Achievements and Business Update at J.P. Morgan Healthcare Conference

Royalty Pharma to Showcase Achievements and Share Business Update at J.P. Morgan Healthcare Conference Royalty Pharma plc today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the…

Read MoreRoyalty Pharma to Showcase Achievements and Business Update at J.P. Morgan Healthcare Conference
Hippocratic

BCG and Hippocratic AI Form Strategic Alliance to Deploy Agentic AI in Biopharma and Medtech

BCG and Hippocratic AI Announce Strategic Collaboration to Deploy Agentic AI Across Biopharma and Medtech Boston Consulting Group (BCG) and Hippocratic AI today announced a global collaboration aimed at transforming the biopharma and medtech industries through the responsible implementation of…

Read MoreBCG and Hippocratic AI Form Strategic Alliance to Deploy Agentic AI in Biopharma and Medtech

Enanta Pharmaceuticals Updates Research Pipeline and Development Strategy for 2026

Highlights recent progress across key R&D programs and outlines strategic priorities for 2026 Enanta Pharmaceuticals, Inc. a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs…

Read MoreEnanta Pharmaceuticals Updates Research Pipeline and Development Strategy for 2026

Rick R. Suarez Appointed U.S. President and Head of the BioPharmaceuticals Business Unit

The appointment strengthens leadership of the company’s U.S. BioPharmaceuticals operations and strategic growth AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.Suarez will lead the execution of the Company’s previously…

Read MoreRick R. Suarez Appointed U.S. President and Head of the BioPharmaceuticals Business Unit
Ironwood

Ironwood Pharmaceuticals Confirms FY 2025 Financial Outlook and Provides FY 2026 Financial Projections

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance BOSTON a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. Throughout…

Read MoreIronwood Pharmaceuticals Confirms FY 2025 Financial Outlook and Provides FY 2026 Financial Projections

Mirum Pharmaceuticals Begins BLOOM Phase 2 Trial with First Patient Dosed Evaluating MRM-3379 for Fragile X Syndrome

Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for rare diseases, announced today a key milestone in its development…

Read MoreMirum Pharmaceuticals Begins BLOOM Phase 2 Trial with First Patient Dosed Evaluating MRM-3379 for Fragile X Syndrome

Hercules Pharmaceuticals Joins Healthcare Distribution Alliance; Timothy Ward Appointed to Board

Hercules Pharmaceuticals Announces Membership in the Healthcare Distribution Alliance and Board Appointment of Timothy Ward Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution and a rapidly growing provider-aligned group purchasing organization (GPO), announced today that it has officially joined…

Read MoreHercules Pharmaceuticals Joins Healthcare Distribution Alliance; Timothy Ward Appointed to Board

Arrowhead Pharmaceuticals Gains FDA Nod for REDEMPLO®, a New Therapy Targeting Triglyceride Reduction in FCS

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran), Marking a Major Advancement in Treatment for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a landmark achievement today with the U.S. Food and Drug Administration’s (FDA) approval of REDEMPLO® (plozasiran).…

Read MoreArrowhead Pharmaceuticals Gains FDA Nod for REDEMPLO®, a New Therapy Targeting Triglyceride Reduction in FCS